NCT02094937View on ClinicalTrials.gov

A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

430

Participants

Timeline

Start Date

March 27, 2014

Primary Completion Date

August 28, 2015

Study Completion Date

August 28, 2015

Conditions
Asthma
Interventions
DRUG

Fluticasone Furoate/Vilanterol

FF/VI 100mg/25 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler

DRUG

Fluticasone Furoate 100 mcg

FF 100 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler

DRUG

Fluticasone Propionate 250 mcg

FP 250 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler

DRUG

Fluticasone Propionate 100 mcg

FP 100 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler

DRUG

Fluticasone Furoate Placebo

Matching placebo of Fluticasone Furoate will be given once daily in the evening via dry powder inhaler

DRUG

Fluticasone Propionate Placebo

Matching placebo of Fluticasone Propionate will be given twice daily (morning and evening) via dry powder inhaler

Trial Locations (33)

036-8545

GSK Investigational Site, Aomori

802-0052

GSK Investigational Site, Fukuoka

811-1394

GSK Investigational Site, Fukuoka

816-0813

GSK Investigational Site, Fukuoka

832-0059

GSK Investigational Site, Fukuoka

509-6134

GSK Investigational Site, Gifu

732-0052

GSK Investigational Site, Hiroshima

672-8064

GSK Investigational Site, Hyōgo

302-0022

GSK Investigational Site, Ibaraki

319-1113

GSK Investigational Site, Ibaraki

760-0018

GSK Investigational Site, Kagawa

760-8538

GSK Investigational Site, Kagawa

761-8073

GSK Investigational Site, Kagawa

762-0031

GSK Investigational Site, Kagawa

239-0821

GSK Investigational Site, Kanagawa

252-0143

GSK Investigational Site, Kanagawa

780-0901

GSK Investigational Site, Kochi

612-0026

GSK Investigational Site, Kyoto

514-1101

GSK Investigational Site, Mie

515-8544

GSK Investigational Site, Mie

560-0005

GSK Investigational Site, Osaka

870-0921

GSK Investigational Site, Ōita

343-0808

GSK Investigational Site, Saitama

103-0027

GSK Investigational Site, Tokyo

104-8560

GSK Investigational Site, Tokyo

140-0011

GSK Investigational Site, Tokyo

140-0013

GSK Investigational Site, Tokyo

145-0063

GSK Investigational Site, Tokyo

171-0014

GSK Investigational Site, Tokyo

187-0002

GSK Investigational Site, Tokyo

190-0014

GSK Investigational Site, Tokyo

191-0031

GSK Investigational Site, Tokyo

204-8522

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02094937 - A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects | Biotech Hunter | Biotech Hunter